Search Medical Condition
Please enter condition
Please choose location from dropdown

Tempe, Arizona Clinical Trials

A listing of Tempe, Arizona clinical trials actively recruiting patient volunteers.

RESULTS

Found (668) clinical trials

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to ...

Phase

9.99 miles

Learn More »

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

This Phase 1 study will enroll approximately 36 evaluable adult subjects with refractory, advanced cancer (solid tumors) regardless of diagnosis and prior therapies. Subjects who discontinue early for reason other than DLT will be replaced. The biopharmacological properties of the antibody suggest that this proposed dose range will be safe ...

Phase

9.99 miles

Learn More »

A Dose Escalation Study of PF 06939999 in Participants With Advanced or Metastatic Solid Tumors.

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

Phase

9.99 miles

Learn More »

A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

Phase

9.99 miles

Learn More »

A Study of CC-95251 a Monoclonal Antibody Directed Against SIRP in Subjects With Advanced Solid and Hematologic Cancers

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B & Part C), first-in-human clinical study of CC-95251 in subjects with advanced solid & hematologic cancers. The dose escalation part (Part A) of the study will be conducted in three stages. Stage 1 will evaluate ...

Phase

9.99 miles

Learn More »

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

This is a prospective, open-label, multicenter, single and repeat-dose study designed to evaluate the reliability and sensitivity of TUV assessments in HCs and subjects with active RA. This study is stratified into 3 arms. The first 2 arms, comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on ...

Phase

9.99 miles

Learn More »

Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors

This open-label, phase 1b/2 dose-escalation and dose-expansion study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of RMC-4630 in combination with cobimetinib in participants with relapsed/refractory solid tumors.

Phase

9.99 miles

Learn More »

Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies

This is a multicenter, open-label, safety, tolerability, pharmacokinetic, and activity study. Eligible subjects will be adults with advanced solid tumor malignancies. In the treatment period groups of 3 to 6 subjects will receive a single dose of oral Oratopo will be administered and will be followed for toxicity. Dose escalation ...

Phase

9.99 miles

Learn More »

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma

This Phase I study is an open-label, dose-escalation trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of the novel anti-cancer compound, GZ17-6.02. GZ17-6.02 is administered orally to patients with advanced solid tumors or lymphoma.

Phase

9.99 miles

Learn More »

IRX-2 Cyclophosphamide and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

PRIMARY OBJECTIVES: I. To determine the safety profile of combination IRX?2 regimen and nivolumab in anti?PD?1/PD?L1 naive patients who have failed or not tolerated at least one line of treatment. SECONDARY OBJECTIVES: I. To evaluate the overall response rate of IRX?2 regimen combined with nivolumab using Response Evaluation Criteria in ...

Phase

9.99 miles

Learn More »